Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -261.31% | -30.76% | -1.40% | 39.09% | 9.46% |
| Total Depreciation and Amortization | -77.27% | 0.00% | 0.00% | 0.00% | 10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11,142.61% | -16.20% | 5.36% | 4.50% | 5.50% |
| Change in Net Operating Assets | 116.50% | 4,681.05% | -65.51% | -391.74% | 352.14% |
| Cash from Operations | -62.51% | 26.52% | -23.44% | -67.36% | 25.65% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 240.00% | -26.11% | -7.59% | 61.33% | -55.95% |
| Total Debt Repaid | -27.27% | 7.92% | -18.08% | -121.71% | 48.12% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 291.07% | -27.94% | -10.27% | 51.46% | -57.49% |
| Foreign Exchange rate Adjustments | 96.20% | -76.19% | 120.00% | 66.67% | -2,470.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 67.53% | -51.18% | -560.21% | -139.35% | -37.12% |